|Day Low/High||5.62 / 5.74|
|52 Wk Low/High||5.18 / 11.26|
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the publication of two manuscripts detailing results of the company's phase 3 Rejoice Trial in Menopause: The Journal of The...
We didn't trade in the model portfolio this week, but several of our holdings made big moves so far this year.
TherapeuticsMD is up 9.7% in the first two trading days of 2017, and we're maintaining our $12.50 price target.
Sirius, Medtronic and Carlyle could be money makers in 2017, says Jim Cramer.
Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that the company will present at the 35 th Annual J.
We closed out a number of holdings for big gains in 2016, including McDermott, Cott and CECO Environmental.
We didn't make any trades this week but are keeping 40% of the portfolio in cash to add names as opportunities arise.
We bought more TherapeuticsMD and Yamana Gold using proceeds from the sale of some Orasure shares.
Cantor Fitzgerald initiated coverage of the company overnight with $34 price target.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company headquartered in Boca Raton, announced the company's participation in the 2016 BioFlorida Conference to be held in Jacksonville from December...
We bought shares of TherapeuticsMD but still have a large portion of the portfolio in cash.
With a stock up 400%, what's not to like about Pioneer Natural Resources? Cramer says.
Stocks once considered free of risks aren't any longer, Cramer warns.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced positive top-line results from its pivotal phase 3 Replenish Trial of TX-001HR, an investigational bio-identical hormone...
We booked some profits in Huntington Bancshares and SLM this week and cut our rating on SLM from One to Two.
Jim Cramer prefers Newell over Berry Plastics and says International Paper is an inexpensive stock with a good yield.
Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.
Our research suggests the risk/reward potential is attractive at current levels.
Builders FirstSource, Huntington Bancshares and TherapeuticsMD all received upbeat outlooks from analysts overnight.
Investors in TherapeuticsMD, Inc. saw new options begin trading today, for the January 2017 expiration.
We booked some profits in Synovus Financial and used part of the proceeds to buy more Yamana Gold.
We sold the rest of our Datalink holdings and will use the proceeds to add a name to our portfolio.
SLM, Teligent and TherapeuticsMD are performing well following the surprise presidential election outcome.